• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

正常血压人群中尿6β-羟基皮质醇/皮质醇比值与CYP3A5基因多态性的关联

Association between urinary 6β-hydroxycortisol/cortisol ratio and CYP3A5 genotypes in a normotensive population.

作者信息

Rais Naushad, Hussain Arif, Chawla Yogesh Kumar, Kohli Krishan K

机构信息

Department of Biotechnology, Manipal University, Dubai, United Arab Emirates ;

出版信息

Exp Ther Med. 2013 Feb;5(2):527-532. doi: 10.3892/etm.2012.842. Epub 2012 Nov 29.

DOI:10.3892/etm.2012.842
PMID:23404385
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3570147/
Abstract

Genetic polymorphism of genes involved in renal salt handling and arterial vessel tone is considered to be one of the causes of hypertension. Numerous reports suggest that cytochrome P4503A5 (CYP3A5) catalyzes 6β-hydroxylation of endogenous cortisol (CS), which is associated with sodium and water retention in the kidney and involved in the regulation of blood pressure. The purpose of the present study was to study the associations of single nucleotide polymorphisms in the CYP3A5 gene with the urinary 6β-hydroxycortisol/cortisol (6β-OH-CS/CS) ratio considered as quantitative phenotypes. CS measurements of three hundred (n=300) healthy, normotensive North Indian individuals was performed on morning spot urine samples by high-performance liquid chromatography. Furthermore, genotyping for CYP3A53 and CYP3A56 was performed by PCR-RFLP. The results indicated a unimodal distribution of CYP3A phenotypes in the North Indian population. In further analysis, all the phenotypes were distributed into three groups, demonstrating low (n=75), intermediate (n=150) and high CYP3A activity (n=75) based on CS and 6β-OH-CS levels and log 6β-OH-CS/CS ratios. The subjects in the low and high activity groups were genotyped for the CYP3A53 and 6 alleles. The present study demonstrated that the allele frequencies of CYP3A51 and 3 were 0.29 (95% CI, 0.22-0.36) and 0.71 (95% CI, 0.64-0.78), respectively. Notably, the frequency of normal homozygotes (CYP3A51/1) was significantly higher in the high activity than the low activity group (11% vs. 5%). Similarly, the frequency of mutant homozygotes (CYP3A53/3) was significantly higher in the low activity group than the high activity group (57% vs. 44%). The allele frequency of CYP3A53 was significantly higher in the low activity group (0.76) than the high activity group (0.67). The mean 6β-OH-CS/CS ratios were 110, 76 and 69 in wild-type homozygotes (n=12), heterozygotes (n=62) and mutant homozygotes (n=76), respectively. The difference between the normal and mutant homozygotes was statistically significant (P<0.05). The CYP3A56 allele was absent from all the subjects genotyped. This is the first study to report the genetic polymorphism of CYP3A5 in a North Indian population and its association with urinary 6β-OH-CS/CS ratio reflecting the CYP3A phenotypes.

摘要

参与肾脏盐处理和动脉血管张力调节的基因的遗传多态性被认为是高血压的病因之一。众多报告表明,细胞色素P4503A5(CYP3A5)催化内源性皮质醇(CS)的6β-羟化反应,这与肾脏中的钠和水潴留有关,并参与血压调节。本研究的目的是研究CYP3A5基因单核苷酸多态性与被视为定量表型的尿6β-羟基皮质醇/皮质醇(6β-OH-CS/CS)比值之间的关联。通过高效液相色谱法对300名健康、血压正常的北印度个体的晨尿样本进行CS测量。此外,通过PCR-RFLP对CYP3A53和CYP3A56进行基因分型。结果表明,CYP3A表型在北印度人群中呈单峰分布。在进一步分析中,根据CS和6β-OH-CS水平以及log 6β-OH-CS/CS比值,将所有表型分为三组,分别显示低(n=75)、中(n=150)和高CYP3A活性(n=75)。对低活性和高活性组的受试者进行CYP3A53和6等位基因的基因分型。本研究表明,CYP3A51和3的等位基因频率分别为0.29(95%CI,0.22-0.36)和0.71(95%CI,0.64-0.78)。值得注意的是,高活性组中正常纯合子(CYP3A51/1)的频率显著高于低活性组(11%对5%)。同样,低活性组中突变纯合子(CYP3A53/3)的频率显著高于高活性组(57%对44%)。低活性组中CYP3A53的等位基因频率(0.76)显著高于高活性组(0.67)。野生型纯合子(n=12)、杂合子(n=62)和突变型纯合子(n=76)的平均6β-OH-CS/CS比值分别为110、76和69。正常纯合子与突变纯合子之间的差异具有统计学意义(P<0.05)。所有进行基因分型的受试者均未检测到CYP3A56等位基因。这是首次报道北印度人群中CYP3A5的遗传多态性及其与反映CYP3A表型的尿6β-OH-CS/CS比值之间的关联。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c149/3570147/5e0ffc99643f/ETM-05-02-0527-g03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c149/3570147/3a3d35f78dd1/ETM-05-02-0527-g00.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c149/3570147/6357b4b37fcb/ETM-05-02-0527-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c149/3570147/1e17537c9c63/ETM-05-02-0527-g02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c149/3570147/5e0ffc99643f/ETM-05-02-0527-g03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c149/3570147/3a3d35f78dd1/ETM-05-02-0527-g00.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c149/3570147/6357b4b37fcb/ETM-05-02-0527-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c149/3570147/1e17537c9c63/ETM-05-02-0527-g02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c149/3570147/5e0ffc99643f/ETM-05-02-0527-g03.jpg

相似文献

1
Association between urinary 6β-hydroxycortisol/cortisol ratio and CYP3A5 genotypes in a normotensive population.正常血压人群中尿6β-羟基皮质醇/皮质醇比值与CYP3A5基因多态性的关联
Exp Ther Med. 2013 Feb;5(2):527-532. doi: 10.3892/etm.2012.842. Epub 2012 Nov 29.
2
CYP3A phenotypes and genotypes in North Indians.北印度人的CYP3A表型和基因型
Eur J Clin Pharmacol. 2006 Jun;62(6):417-22. doi: 10.1007/s00228-006-0105-3. Epub 2006 Apr 21.
3
Associations of the CYP3A5*3 and CYP3A4*1G polymorphisms with the pharmacokinetics of oral midazolam and the urinary 6β-hydroxycortisol/cortisol ratio as markers of CYP3A activity in healthy male Chinese.在中国健康男性中,CYP3A5*3和CYP3A4*1G基因多态性与口服咪达唑仑的药代动力学以及作为CYP3A活性标志物的尿6β-羟基皮质醇/皮质醇比值的相关性。
J Clin Pharm Ther. 2016 Oct;41(5):552-8. doi: 10.1111/jcpt.12433. Epub 2016 Aug 11.
4
Genotype-phenotype variability in human CYP3A locus in Nepalese people residing in Bangladesh.居住在孟加拉国的尼泊尔人群中人类CYP3A基因座的基因型-表型变异性。
Int J Clin Pharmacol Ther. 2013 Mar;51(3):207-14. doi: 10.5414/CP201831.
5
A wide interindividual variability of urinary 6beta-hydroxycortisol to free cortisol in 487 healthy Japanese subjects in near basal condition.487名处于接近基础状态的健康日本受试者尿中6β-羟基皮质醇与游离皮质醇的个体间差异很大。
Ther Drug Monit. 2002 Dec;24(6):722-7. doi: 10.1097/00007691-200212000-00007.
6
Genotypes and phenotypes of CYP3A in Bangladeshi population.孟加拉国人群 CYP3A 的基因型和表型。
Clin Chim Acta. 2011 Mar 18;412(7-8):531-6. doi: 10.1016/j.cca.2010.11.031. Epub 2010 Nov 27.
7
Dose-dependent inhibition of CYP3A activity by clarithromycin during Helicobacter pylori eradication therapy assessed by changes in plasma lansoprazole levels and partial cortisol clearance to 6beta-hydroxycortisol.通过血浆兰索拉唑水平变化和部分皮质醇清除为6β-羟基皮质醇来评估克拉霉素在幽门螺杆菌根除治疗期间对CYP3A活性的剂量依赖性抑制。
Clin Pharmacol Ther. 2002 Jul;72(1):33-43. doi: 10.1067/mcp.2002.125559.
8
Interindividual and intraindividual variability of the urinary 6beta-Hydroxycortisol/Cortisol ratio in Chinese subjects: implications of its use for evaluating CYP3A activity.中国受试者尿中6β-羟基皮质醇/皮质醇比值的个体间和个体内变异性:其用于评估CYP3A活性的意义
J Clin Pharmacol. 2004 Dec;44(12):1412-7. doi: 10.1177/0091270004269760.
9
Genotyping and phenotyping CYP3A4\CYP3A5: no association with antiplatelet effect of clopidogrel.CYP3A4\CYP3A5 基因型和表型分析:与氯吡格雷抗血小板作用无关。
Mol Biol Rep. 2019 Aug;46(4):4195-4199. doi: 10.1007/s11033-019-04871-y. Epub 2019 May 17.
10
The influence of taurine and L-carnitine on 6 β-hydroxycortisol/cortisol ratio in human urine of healthy volunteers.牛磺酸和左旋肉碱对健康志愿者尿中6β-羟基皮质醇/皮质醇比值的影响。
Drug Metab Pers Ther. 2019 Oct 11;34(3):dmpt-2019-0013. doi: 10.1515/dmpt-2019-0013.

引用本文的文献

1
Precision medication based on the evaluation of drug metabolizing enzyme and transporter functions.基于药物代谢酶和转运体功能评估的精准药物治疗。
Precis Clin Med. 2025 Feb 22;8(1):pbaf004. doi: 10.1093/pcmedi/pbaf004. eCollection 2025 Mar.
2
Relevance of plasma lenvatinib concentrations and endogenous urinary cytochrome P450 3A activity biomarkers in clinical practice.血浆仑伐替尼浓度与内源性尿细胞色素 P4503A 活性生物标志物在临床实践中的相关性。
Pharmacol Res Perspect. 2024 Aug;12(4):e1241. doi: 10.1002/prp2.1241.
3
The Role of Cytochrome P450 Enzymes in COVID-19 Pathogenesis and Therapy.

本文引用的文献

1
CYP3A5 genotype-phenotype analysis in the human kidney reveals a strong site-specific expression of CYP3A5 in the proximal tubule in carriers of the CYP3A5*1 allele.CYP3A5 基因型-表型分析在人类肾脏中揭示了 CYP3A5 在 CYP3A5*1 等位基因携带者的近端肾小管中的强特异性表达。
Drug Metab Dispos. 2012 Apr;40(4):639-41. doi: 10.1124/dmd.111.042648. Epub 2012 Jan 3.
2
Assessment of the impact of CYP3A polymorphisms on the formation of α-hydroxytamoxifen and N-desmethyltamoxifen in human liver microsomes.评估 CYP3A 多态性对人肝微粒体中 α-羟他莫昔芬和 N-去甲基他莫昔芬形成的影响。
Drug Metab Dispos. 2012 Feb;40(2):389-96. doi: 10.1124/dmd.111.039388. Epub 2011 Nov 17.
3
细胞色素P450酶在新型冠状病毒肺炎发病机制及治疗中的作用
Front Pharmacol. 2022 Feb 2;13:791922. doi: 10.3389/fphar.2022.791922. eCollection 2022.
Association of the CYP3A5 polymorphism (6986G>A) with blood pressure and hypertension.
CYP3A5 多态性(6986G>A)与血压和高血压的关联。
Hypertens Res. 2011 Nov;34(11):1216-20. doi: 10.1038/hr.2011.112. Epub 2011 Aug 4.
4
CYP3A5 polymorphism and sensitivity of blood pressure to dietary salt in Japanese men.CYP3A5 多态性与日本男性血压对盐饮食的敏感性
J Hum Hypertens. 2010 May;24(5):345-50. doi: 10.1038/jhh.2009.74. Epub 2009 Oct 8.
5
CYP3A5 and ABCB1 genes influence blood pressure and response to treatment, and their effect is modified by salt.CYP3A5和ABCB1基因影响血压及治疗反应,且其作用受盐的影响。
Hypertension. 2007 May;49(5):1007-14. doi: 10.1161/HYPERTENSIONAHA.106.084236. Epub 2007 Mar 19.
6
Association of CYP3A5 polymorphisms with hypertension and antihypertensive response to verapamil.细胞色素P450 3A5基因多态性与高血压及维拉帕米降压反应的关联
Clin Pharmacol Ther. 2007 Mar;81(3):386-91. doi: 10.1038/sj.clpt.6100090.
7
CYP3A phenotypes and genotypes in North Indians.北印度人的CYP3A表型和基因型
Eur J Clin Pharmacol. 2006 Jun;62(6):417-22. doi: 10.1007/s00228-006-0105-3. Epub 2006 Apr 21.
8
Significance of the minor cytochrome P450 3A isoforms.细胞色素P450 3A次要同工型的意义。
Clin Pharmacokinet. 2006;45(1):13-31. doi: 10.2165/00003088-200645010-00002.
9
Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus.CYP3A5对他克莫司体外肝脏清除率的贡献。
Clin Chem. 2005 Aug;51(8):1374-81. doi: 10.1373/clinchem.2005.050047. Epub 2005 Jun 10.
10
Association between the CYP3A5 genotype and blood pressure.细胞色素P450 3A5(CYP3A5)基因与血压之间的关联。
Hypertension. 2005 Feb;45(2):294-8. doi: 10.1161/01.HYP.0000151361.31736.96. Epub 2004 Dec 13.